196 related articles for article (PubMed ID: 32372174)
1. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study.
Beer A; Taghizadeh H; Schiefer AI; Puhr HC; Karner AK; Jomrich G; Schoppmann SF; Kain R; Preusser M; Ilhan-Mutlu A
Pathol Oncol Res; 2020 Oct; 26(4):2225-2235. PubMed ID: 32372174
[TBL] [Abstract][Full Text] [Related]
2. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy.
Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT
Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
4. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
8. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
10. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
11. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Lin EM; Gong J; Klempner SJ; Chao J
World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
[TBL] [Abstract][Full Text] [Related]
12. Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
Oki E; Okano S; Saeki H; Umemoto Y; Teraishi K; Nakaji Y; Ando K; Zaitsu Y; Yamashita N; Sugiyama M; Nakashima Y; Ohgaki K; Oda Y; Maehara Y
Oncology; 2017; 93(6):387-394. PubMed ID: 28910818
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance.
Lian J; Zhang G; Zhang Y; Liu H; Zhang J; Nan P; Tian W
Dig Liver Dis; 2022 Oct; 54(10):1419-1427. PubMed ID: 35123909
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA; Kennedy EB; Alarcon-Rozas AE; Alcindor T; Bartley AN; Malowany AB; Bhadkamkar NA; Deighton DC; Janjigian Y; Karippot A; Khan U; King DA; Klute K; Lacy J; Lee JJ; Mehta R; Mukherjee S; Nagarajan A; Park H; Saeed A; Semrad TJ; Shitara K; Smyth E; Uboha NV; Vincelli M; Wainberg Z; Rajdev L
J Clin Oncol; 2023 Mar; 41(7):1470-1491. PubMed ID: 36603169
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
17. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Chen L; Wang L; Li X; Zhang G; Li Z; Wang Y
DNA Cell Biol; 2021 Feb; 40(2):405-413. PubMed ID: 33605797
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
19. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
20. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]